Finnish Perspective on Drug-Impaired Driving Finds Cannabis Among Top Substances Detected

Review of drug-impaired driving policies and data across Europe found illicit drug prevalence of 1-5% among general drivers, with cannabis, amphetamines, benzodiazepines, and opiates among the most concerning substances for driving safety.

Lillsunde, P et al.·Bulletin on narcotics·2005·Moderate EvidenceReview
RTHC-00196ReviewModerate Evidence2005RETHINKTHC RESEARCH DATABASErethinkthc.com/research

Quick Facts

Study Type
Review
Evidence
Moderate Evidence
Sample
Not reported

What This Study Found

This review examined drug-impaired driving from a Finnish and European perspective. It reported that the prevalence of illicit drug use among the general driving population in Europe ranged from 1-5%, while licit drugs affecting driving (particularly benzodiazepines) had a prevalence of 5-10%.

Drugs identified as most concerning for driving impairment included amphetamines, cocaine, cannabis, opiates, and benzodiazepines. The review discussed evolving legal frameworks, noting that some countries had introduced zero-tolerance per se laws that prohibit driving with any detectable level of illicit drugs or metabolites, regardless of demonstrated impairment.

The review also discussed advancing roadside testing technology, including oral fluid (saliva) testing. Legislation in Victoria, Australia already allowed oral fluid testing for cannabis and methamphetamine, though blood testing remained the most common form of evidentiary testing in most jurisdictions.

Key Numbers

Illicit drug prevalence in European general driving population: 1-5%. Licit drug prevalence affecting driving: 5-10%. Most concerning drugs: amphetamines, cocaine, cannabis, opiates, benzodiazepines. Some countries adopted zero-tolerance per se laws.

How They Did This

Review article examining drug-impaired driving from a Finnish perspective, covering prevalence data, legal frameworks across countries, detection methods (blood, oral fluid, urine), and enforcement approaches. Drew on epidemiological data from drivers, offenders, and crash-involved populations.

Why This Research Matters

As cannabis legalization has expanded since this review, the question of drug-impaired driving has become increasingly important. The distinction between zero-tolerance approaches (any detectable level) and impairment-based approaches (demonstrated functional impairment) remains a central policy debate.

The Bigger Picture

The debate over how to define and enforce drug-impaired driving has only intensified as more jurisdictions legalize cannabis. The fundamental challenge remains: unlike alcohol, there is no established relationship between blood THC levels and degree of driving impairment, making per se limits controversial.

What This Study Doesn't Tell Us

The review focused on the Finnish and European context, which may not generalize to other regions. Data on drug prevalence among drivers varied in quality across countries. The review did not establish specific impairment thresholds for individual drugs.

Questions This Raises

  • ?Can roadside testing technology reliably detect cannabis impairment as opposed to mere recent use?
  • ?Is a zero-tolerance approach or an impairment-based approach more effective for cannabis-impaired driving enforcement?

Trust & Context

Key Stat:
1-5% of European drivers tested positive for illicit drugs; 5-10% for licit drugs affecting driving
Evidence Grade:
Review article compiling epidemiological data and policy analysis from multiple European countries. Provides a broad overview but limited by varying data quality across jurisdictions.
Study Age:
Published in 2005. Drug-impaired driving detection technology and legislation have evolved substantially since then, particularly as cannabis legalization has expanded.
Original Title:
Drugs and driving: the Finnish perspective.
Published In:
Bulletin on narcotics, 57(1-2), 213-29 (2005)
Database ID:
RTHC-00196

Evidence Hierarchy

Meta-Analysis / Systematic Review
Randomized Controlled Trial
Cohort / Case-Control
Cross-Sectional / ObservationalSnapshot without intervening
This study
Case Report / Animal Study

Summarizes existing research on a topic.

What do these levels mean? →

Frequently Asked Questions

How common is drug-impaired driving?

This review estimated 1-5% of European general population drivers tested positive for illicit drugs, with another 5-10% positive for licit drugs that affect driving ability (primarily benzodiazepines). Rates were higher among those involved in crashes or suspected of impaired driving.

Can police test for cannabis at the roadside?

As of 2005, some jurisdictions (notably Victoria, Australia) had implemented oral fluid roadside testing for cannabis. Most countries still relied on blood testing for evidentiary purposes. Roadside detection technology has continued to advance since then.

Read More on RethinkTHC

Cite This Study

RTHC-00196·https://rethinkthc.com/research/RTHC-00196

APA

Lillsunde, P; Gunnar, T. (2005). Drugs and driving: the Finnish perspective.. Bulletin on narcotics, 57(1-2), 213-29.

MLA

Lillsunde, P, et al. "Drugs and driving: the Finnish perspective.." Bulletin on narcotics, 2005.

RethinkTHC

RethinkTHC Research Database. "Drugs and driving: the Finnish perspective." RTHC-00196. Retrieved from https://rethinkthc.com/research/lillsunde-2005-drugs-and-driving-the

Access the Original Study

Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.

This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.